سیویلیکا را در شبکه های اجتماعی دنبال نمایید.

High-dose dual therapy with a clavulanic acid component for Helicobacter pylori infection treatment: A Randomized Controlled Trial

Publish Year: 1400
Type: Conference paper
Language: English
View: 389

This Paper With 6 Page And PDF Format Ready To Download

Export:

Link to this Paper:

Document National Code:

HSEBCNF04_021

Index date: 2 November 2021

High-dose dual therapy with a clavulanic acid component for Helicobacter pylori infection treatment: A Randomized Controlled Trial abstract

Background: Several drug regimens such as Dual and quadruple therapy are used to eradicate Helicobacter pylori. This study was performed to compare the Dual therapy (DT) regimen (Rabeprazole, Amoxicillin, and Co-Amoxiclav) and the quadruple therapy (QT) regimen group (Rabeprazole, Amoxicillin, Metronidazole, and Bismuth) to eradicate Helicobacter pylori (H. pylori).Methods: 220 eligible patients were included in the study (108 in the DT and 112 in the QT group). Randomization will be performed in a simple randomization method by using a table of random numbers and patients were divided into two groups. The DT regimen consisted of amoxicillin 500 mg three times daily (TDS) with Co-amoxiclav 625 mg TDS and Rabeprazole 20 mg TDS for two weeks. The standard QT regimen included amoxicillin 1000 mg twice daily (BID), bismuth 500 mg BID, metronidazole 500 mg BID, and rabeprazole BID for two weeks. Two weeks after the end of the treatment period, patients were evaluated for eradication of H. pylori with H. pylori stool antigen test.Results: 104 patients in the DT group and 106 people in the QT group were able to complete the treatment course. The eradication rate was 86.54% (n = 90) and 88.46% (n = 92) in the quadruple and dual drug treatment groups, respectively. No significant difference was observed between the two groups in H. pylori eradication rate (P=0.544).Conclusion: According to this study, it can be concluded that adding the clavulanic acid component to the eradication regimen has no effect and is not recommended.

High-dose dual therapy with a clavulanic acid component for Helicobacter pylori infection treatment: A Randomized Controlled Trial Keywords:

Helicobacter pylori , Rabeprazole , Co-amoxiclav , High dose dual drug therapy

High-dose dual therapy with a clavulanic acid component for Helicobacter pylori infection treatment: A Randomized Controlled Trial authors

Arezoo Delshad

Department of internal medicine, Urmia University of Medical Science, Urmia, Iran.

Mohammad Reza Mohammad Hoseiniazar

Department of internal medicine, Gastroenterology and Hepatology section, Urmia University of Medical Science, Urmia, Iran.

Mohammad Reza Pashaei

Department of internal medicine, Gastroenterology and Hepatology section, Urmia University of Medical Science, Urmia, Iran.